Clinical Trials

Below is a listing of clinical trials conducted at MUSC Hollings Cancer Center. Use the tools in the left toolbar to refine your search. If you are interested in Early Phase/Multi Tumor trials, select the program “Phase I Unit.” Please note that cohort information for the phase I trials change often.






Protocol Title Status Contact
103560 A Dose Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single Agent and Combination Therapy in Subjects With Inoperable Locally Advanced or Metastatic Solid Tumors OPEN TO ACCRUAL Contact
103645 A Randomized Phase II Trial of Triplet Therapy (A PDL1 Inhibitor Durvalumab (MEDI4736) in Combination with Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women with Platinum Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab OPEN TO ACCRUAL Contact
103627 Randomized Phase II/III Trial of Radiation with High Dose Cisplatin (100mg/m2) Every Three Weeks Versus Radiation with Low Dose Cisplatin (40mg/m2) for Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) OPEN TO ACCRUAL Contact
103632 A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy With or Without SBRT for PD L1 Negative, Advanced Non Small Cell Lung Cancer OPEN TO ACCRUAL Contact
103646 A Phase II/III Study of Peri operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma OPEN TO ACCRUAL Contact
103664 Phase III Study of Local or Systemic Therapy Intensification Directed by PET in Prostate Cancer Patients with Post Prostatectomy Biochemical Recurrence (INDICATE) OPEN TO ACCRUAL Contact
103643 A Phase II/III Study of N 803 (ALT 803) Plus Pembrolizumab Versus Standard of Care in Participants With Stage IV or Recurrent Non Small Cell Lung Cancer Previously Treated With Anti PD 1 or Anti PD L1 Therapy (Lung MAP Non Match Sub Study) OPEN TO ACCRUAL Contact
103506 A Phase 3 Randomized Non Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1) OPEN TO ACCRUAL Contact
103430 A Phase 1b Study Evaluating the Safety and Efficacy of AMG 757 in Combination with AMG 404 in Subjects with Small Cell Lung Cancer (SCLC) OPEN TO ACCRUAL Contact
103451 Phase 3,Single Arm,Open Label Study Evaluating Ovarian Suppression Following 3 Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination With Endocrine Therapy in Premenopausal Subjects With Hormone Receptor Positive (HR+),Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer OPEN TO ACCRUAL Contact
103219 A Phase 3 Randomized Study of Selumetinib (IND # 77782) Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low Grade Glioma (LGG) OPEN TO ACCRUAL Contact
103487 A Phase 3, Randomized, Double blind Study of Adjuvant Immunotherapy with Relatlimab and Nivolumab Fixed dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III IV Melanoma (RELATIVITY 098) OPEN TO ACCRUAL Contact
103410 An Open Label, Multicenter, Phase 2 Study of CLR 131 in Patients with Relapsed or Refractory (R/R) Select B Cell Malignancies (CLOVER 1) and Expansion Cohort in Patients with Waldenstrom Macroglobulinemia (CLOVER WaM) OPEN TO ACCRUAL Contact
103593 A SAFETY RUN IN AND PHASE II STUDY EVALUATING THE EFFICACY, SAFETY, AND IMPACT ON THE TUMOR MICROENVIRONMENT OF THE COMBINATION OF TOCILIZUMAB, ATEZOLIZUMAB, AND FRACTIONATED STEREOTACTIC RADIOTHERAPY IN RECURRENT GLIOBLASTOMA OPEN TO ACCRUAL Contact
103384 Phase 3, Multicenter, Double Blind, Randomized, Placebo Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF 302) OPEN TO ACCRUAL Contact
103485 A Phase 1/2 Study of REGN5093 M114 (METxMET Antibody Drug Conjugate) in Patients with MET Overexpressing Advanced Cancer OPEN TO ACCRUAL Contact
103365 An Open Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Patients with Epstein Barr Virus Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL 1) OPEN TO ACCRUAL Contact
103625 Exploratory clinical trial of topical Imiquimod 5% cream as window of opportunity monotherapy for early stage oral cancer OPEN TO ACCRUAL Contact
103434 A Phase 1b Open Label Study to Evaluate the Safety and Anti cancer Activity of Loncastuximab Tesirine in Combination with Other Anti cancer Agents in Patients with Relapsed or Refractory B cell Non Hodgkin Lymphoma (LOTIS 7) OPEN TO ACCRUAL Contact
103164 A Phase 1 Study of SEA CD70 in Myeloid Malignancies OPEN TO ACCRUAL Contact